AU1725197A - Use of nitric oxid synthase inhibitors for the treatment of diabetes - Google Patents

Use of nitric oxid synthase inhibitors for the treatment of diabetes

Info

Publication number
AU1725197A
AU1725197A AU17251/97A AU1725197A AU1725197A AU 1725197 A AU1725197 A AU 1725197A AU 17251/97 A AU17251/97 A AU 17251/97A AU 1725197 A AU1725197 A AU 1725197A AU 1725197 A AU1725197 A AU 1725197A
Authority
AU
Australia
Prior art keywords
diabetes
treatment
synthase inhibitors
nitric oxid
oxid synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17251/97A
Inventor
Valerie Piercy
Nicholas Charles Turner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU1725197A publication Critical patent/AU1725197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU17251/97A 1997-02-13 1997-02-13 Use of nitric oxid synthase inhibitors for the treatment of diabetes Abandoned AU1725197A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/000691 WO1998035667A1 (en) 1997-02-13 1997-02-13 Use of nitric oxid synthase inhibitors for the treatment of diabetes

Publications (1)

Publication Number Publication Date
AU1725197A true AU1725197A (en) 1998-09-08

Family

ID=8166520

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17251/97A Abandoned AU1725197A (en) 1997-02-13 1997-02-13 Use of nitric oxid synthase inhibitors for the treatment of diabetes

Country Status (5)

Country Link
EP (1) EP0957909A1 (en)
JP (1) JP2001512450A (en)
AU (1) AU1725197A (en)
CA (1) CA2280871A1 (en)
WO (1) WO1998035667A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1537865A1 (en) * 2003-12-03 2005-06-08 Franz-Peter Dr. Liebel Use of sulfur containing compounds and proteolytic enzymes for the prevention and therapy of the UDP-Glucuronosyltransferase 1 deficient Type II Diabetes mellitus
EP1537864A1 (en) * 2003-12-03 2005-06-08 Franz-Peter Dr. Liebel Use of amino acids and sulphur-containing compounds for the prevention and therapy of the UDP Glucuronosyltransferase 1 deficient Type II Diabetes mellitus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012799A1 (en) * 1990-02-28 1991-09-05 The Upjohn Company Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
FR2726186B1 (en) * 1994-10-28 1996-12-27 Centre Nat Rech Scient DRUGS CONTAINING NITRIC OXIDE SYNTHASE INHIBITORS
DE793646T1 (en) * 1994-11-23 1999-12-30 Upjohn Co CARBOXYLATED AMINOGUANIDINE FOR TREATING INSULIN-INDEPENDENT DIABETES MELLITUS

Also Published As

Publication number Publication date
EP0957909A1 (en) 1999-11-24
JP2001512450A (en) 2001-08-21
CA2280871A1 (en) 1998-08-20
WO1998035667A1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
AU4149696A (en) Substituted heterocycles as inhibitors of nitric oxide synthase
AU4430599A (en) Inhibitors of nitric oxide synthase
AU7906100A (en) Use of retigabin for treating neuropathic pain
IL130551A0 (en) Nitric oxide synthase inhibitors
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU5760900A (en) Multiple agent diabetes therapy
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
AU2000276362A1 (en) Composition for the treatment of diabetes
AU7099198A (en) Use of amantadine for treatment of hepatitis c
AU1592799A (en) Surface treatment for metal oxide substrates
HK1041827B (en) Compounds for the treatment of estrogen-defendent illnesses and methods for making and using the same
AU4268796A (en) Acetamidine derivatives and their use as inhibitors for the nitric oxide synthase
AU2512501A (en) Use of trimebutine for treating pain
AU5056099A (en) Compounds for use in the treatment of inflammation
AU8473398A (en) 1,3-diaza- heterocycles and their use as nitric oxide synthase inhibitors
AU1539399A (en) Inhibitors of nitric oxide synthase
GB9810299D0 (en) Use of nitric oxide synthase inhibitors
AU1725197A (en) Use of nitric oxid synthase inhibitors for the treatment of diabetes
AU7653600A (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis
EP1225913B8 (en) Use of nitric oxide for the treatment of airway constriction
AU3783799A (en) Compositions and methods for treating particular chemical addictions and mental illnesses
AU1940800A (en) Combination therapy for the treatment of sepsis
AU2896695A (en) Nitric oxide synthase inhibitors for inhibiting the production of airway mucus
AU2420101A (en) Method and composition for the treatment of pain
AU4107797A (en) Compounds for the treatment and prevention of diabetes